- abnormal apoptosis / MGI
- increased mammary adenocarcinoma incidence / MGI
- increased tumor incidence / MGI
- no abnormal phenotype detected / MGI
- abnormal eosinophil physiology / MGI
- increased hepatocellular carcinoma incidence / MGI
- impaired macrophage chemotaxis / MGI
- increased lung carcinoma incidence / MGI
- increased fibrosarcoma incidence / MGI
- prenatal lethality, incomplete penetrance / MGI
- increased lymphoma incidence / MGI
C57BL/6N-S100a4em1(IMPC)Wtsi/WtsiOrl
Status | Available to order |
EMMA ID | EM:13768 |
International strain name | C57BL/6N-S100a4em1(IMPC)Wtsi/WtsiOrl |
Alternative name | |
Strain type | Endonuclease-mediated |
Allele/Transgene symbol | S100a4em1(IMPC)Wtsi |
Gene/Transgene symbol | S100a4 |
Information from provider
Provider | Wellcome Trust Sanger Institute |
Provider affiliation | Wellcome Trust Sanger Institute |
Genetic information | This mouse line originates from CRISPR zygote microinjection. For further details see the project page at the IMPC portal. |
Phenotypic information | Potential phenotyping data in the IMPC portal |
References | None available |
Information from EMMA
Archiving centre | Institut de Transgenose, INTRAGENE, Orléans, France |
Disease and phenotype information
MGI phenotypes (gene matching)
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).